✦ LIBER ✦

P-348 A phase I trial of gemcitabine followed by flavopiridol in patients with solid tumors

✍ Scribed by Goffin, John; Appleman, Leonard; Ryan, David; Fidias, Panos; Lucca, Joan; Regan, Eileen; Dimitrios Colevas, A.; Eder, Joseph Paul; Supko, Jeffrey; Shapiro, Geoffrey

Book ID: 118572048
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 369 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)92316-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of everolimus, gemcitabine

Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors

✍ Costello, Brian A.; Borad, Mitesh J.; Qi, Yingwei; Kim, George P.; Northfelt, Do 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 164 KB

Phase I trial of sunitinib and gemcitabi

Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors

✍ Joanna M. Brell, Smitha S. Krishnamurthi… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 177 KB

Gemcitabine and Docetaxel in patients wi

Gemcitabine and Docetaxel in patients with advanced solid tumors. A GETICS phase I trial

✍ Jaremtchuk, A.V.; Zabra, J.J.; Ferro, A.; Aman, E.F.; Alvarez, R.; Arroyo, G.; M 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 144 KB

A phase I trial of gemcitabine in combin

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

✍ William Schelman; Sherry Morgan-Meadows; Howard Bailey; Kyle Holen; James P. Tho 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 325 KB

A phase I trial of gemcitabine plus pacl

A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors

✍ Sandler, A.; Raghavan, D.; Meropol, N.; Meyers, T.; Kindler, H.; Fox, S.; Perez, 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 250 KB

Phase I clinical trial of bortezomib in

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi